Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on May 13, 2015. The filing serves to announce the company's financial results for the first quarter ended March 31, 2015, which were originally issued via a press release on March 13, 2015.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within Exhibit 99.1 (the press release), which is furnished with the report but not included in the text of the Form 8-K itself.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the body text. It directs readers to the attached press release for the specific results of operations and financial condition.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished under Item 2.02 and Exhibit 99.1:
- Is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
- Is not incorporated by reference into other filings unless specifically stated.
- Does not constitute an admission that the information is required under Regulation FD.
- Does not obligate the company to update the information in the future.
No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated May 13, 2015), as they are absent from the Form 8-K text.
- Confirm the company name is Imprimis Pharmaceuticals, Inc., noting the discrepancy with the metadata field "HARROW, INC."
- Check the date of the original press release (March 13, 2015) versus the filing date (May 13, 2015) to understand the reporting timeline.